Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
作者信息
Nichols David, Gifford Alex, Russell Renee, Odem-Davis Katherine, Young Julia, Amaro-Galvez Rodolfo, Billings Joanne, Mukadam Zubin, Mayer-Hamblett Nicole
机构信息
University of Washington Seattle, Washington.
Case Western Reserve University Cleveland, Ohio.
出版信息
Ann Am Thorac Soc. 2024 Feb;21(2):360-362. doi: 10.1513/AnnalsATS.202308-735RL.
Abstract
摘要
相似文献
1
Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.评估在接受依列卡福妥/替扎卡福妥/依伐卡福妥治疗后一秒用力呼气量较低的患者中停用高渗盐水的安全性。
Ann Am Thorac Soc. 2024 Feb;21(2):360-362. doi: 10.1513/AnnalsATS.202308-735RL.
2
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.
3
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
4
Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.用于治疗囊性纤维化的依列卡福妥/替扎卡福妥/依伐卡托（三联疗法）
Med Lett Drugs Ther. 2020 Jan 13;62(1589):5-7.
6
Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor.接受依列卡福妥/替扎卡福妥/依伐卡托治疗的成年囊性纤维化患者的睡眠特征
J Cyst Fibros. 2024 Jan;23(1):132-136. doi: 10.1016/j.jcf.2023.05.005. Epub 2023 May 19.
7
Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?依列卡福妥/替扎卡福妥/依伐卡托对治疗囊性纤维化患者的鼻窦疾病有效吗？
Laryngoscope. 2024 Feb;134(2):501-503. doi: 10.1002/lary.30937. Epub 2023 Aug 7.
8
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.VX-445-泰泽卡托维瓦卡托联合治疗伴有一个或两个 Phe508del 等位基因的囊性纤维化患者。
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.
9
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare variants: a viewpoint.收集真实世界的同情用药数据以扩大艾列卡福托/替扎卡福托/依伐卡托对携带N1303K或其他罕见变异的囊性纤维化患者的适用范围：一种观点
Eur Respir J. 2024 Jan 25;63(1). doi: 10.1183/13993003.01959-2023. Print 2024 Jan.
10
Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis.依列卡福妥-替扎卡福妥-依伐卡托可增加囊性纤维化患儿气道一氧化氮水平。
J Cyst Fibros. 2024 Jan;23(1):109-111. doi: 10.1016/j.jcf.2023.05.015. Epub 2023 Oct 21.
引用本文的文献
1
Reducing Treatment Burden in Cystic Fibrosis: Is There a Risk to OverSIMPLIFYing Therapies?减轻囊性纤维化的治疗负担：过度简化治疗方法是否存在风险？
Ann Am Thorac Soc. 2024 Nov;21(11):1483-1484. doi: 10.1513/AnnalsATS.202407-694ED.
2
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.停止使用 Elexacaftor-Tezacaftor-Ivacaftor 后，高渗盐水和脱氧核糖核酸酶 α 对囊性纤维化的影响。
Ann Am Thorac Soc. 2024 Nov;21(11):1507-1515. doi: 10.1513/AnnalsATS.202404-366OC.
本文引用的文献
1
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.调制治疗的囊性纤维化患者中停用或继续使用高渗盐水或脱氧核糖核酸酶 α（SIMPLIFY）：两项平行、多中心、开放标签、随机、对照、非劣效性试验的结果。
Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4.
2
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.评估囊性纤维化调制药物治疗后停止慢性治疗的影响：SIMPLIFY 临床试验研究设计。
Ann Am Thorac Soc. 2021 Aug;18(8):1397-1405. doi: 10.1513/AnnalsATS.202010-1336SD.
3
Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy.响应号召，在高效 CFTR 调节剂治疗时代解决囊性纤维化治疗负担问题。
J Cyst Fibros. 2020 Sep;19(5):762-767. doi: 10.1016/j.jcf.2019.11.007. Epub 2019 Nov 21.
4
Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.确定囊性纤维化问卷修订版呼吸症状量表在两组囊性纤维化合并慢性铜绿假单胞菌气道感染患者中的最小临床重要差异分数。
Chest. 2009 Jun;135(6):1610-1618. doi: 10.1378/chest.08-1190. Epub 2009 May 15.
Zotero 插件